Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| City Therapeutics | 2024 | Series A | $135.0M | Cambridge |
| EGenesis | 2024 | Series D | $191.0M | Cambridge |
| ArsenalBio | 2024 | Series C | $325.0M | South San Francisco |
| Ultivue | 2024 | Series Unknown | $3.3M | Cambridge |
| Autobahn Therapeutics | 2024 | Series C | $100.0M | San Diego |
| Moleculent | 2024 | Series A | $26.0M | Solna |
| Advanced Medicine Partners | 2024 | Series A | $32.0M | Lake Forest |
| Vilya | 2024 | Series A | $21.0M | Seattle |
| Quantum Circuits | 2024 | Series B | $60.0M | New Haven |
| Slingshot Biosciences | 2024 | Series A | $15.0M | Emeryville |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 76 | City Therapeutics | Series A | $135.0M | Cambridge, United States |
| 77 | EGenesis | Series D | $191.0M | Cambridge, United States |
| 78 | ArsenalBio | Series C | $325.0M | South San Francisco, United States |
| 79 | Ultivue | Series Unknown | $3.3M | Cambridge, United States |
| 80 | Autobahn Therapeutics | Series C | $100.0M | San Diego, United States |
| 81 | Moleculent | Series A | $26.0M | Solna, Sweden |
| 82 | Advanced Medicine Partners | Series A | $32.0M | Lake Forest, United States |
| 83 | Vilya | Series A | $21.0M | Seattle, United States |
| 84 | Quantum Circuits | Series B | $60.0M | New Haven, United States |
| 85 | Slingshot Biosciences | Series A | $15.0M | Emeryville, United States |
City Therapeutics is a biopharmaceutical company focused on developing next-generation small interfering RNAs.
EGenesis is a gene editing and genome engineering company developing human-compatible engineered organs to treat diseases.
ArsenalBio is a programmable cell therapy company that offers CAR T-cell therapies for solid tumors.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing.
Clinical stage biotechnology company developing restorative treatments for people affected by neuropsychiatric & neuroimmunologic disorders
Moleculent is the Biotechnology Research company.
Advanced Medicine Partners is a biotechnology company that specializes in viral vector manufacturing for genes and cells.
Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease.
Quantum Circuits is delivering a full-stack quantum computer based on the innovative dual-rail qubit providing superior performance.
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Neumora Therapeutics operates as a clinical-stage biotechnology company.
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.
Over millions and millions of years, a collection of reward systems
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease.
Basking Biosciences is to commercialize technology developed at Duke and Ohio State Universities.
Accompany Health provides comprehensive in-home care to patients who live in sometimes underserved regions.
Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases.
Moonwalk Biosciences operates a genomic medicine company that aims to provide a new class of precision epigenetic medications.
Remix Therapeutics is a biotechnology company that is working on developing small molecule medicines.
Tome Biosciences is a biotechnology company that develops programmable gene insertion technology.
Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.
UltraDx Bio is a biotechnology company that specializes in single-molecule digital high-sensitivity protein detection technology.
Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease.
Qihan Biotech is a gene-editing organ transplantation technology developer.
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
ARCH Venture Partners has invested in 156 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
ARCH Venture Partners's top investment sectors include Biotechnology, Medical, Life Science, Health Care, Therapeutics. The firm invests across 21 different industry categories.
Among tracked funding rounds, Xaira Therapeutics received $1.0B in a Series A round. ARCH Venture Partners's total known invested capital is $9.8B.
ARCH Venture Partners's average investment size is $88.7M across its portfolio of 156 companies.
Recent ARCH Venture Partners portfolio additions include City Therapeutics, EGenesis, ArsenalBio, Ultivue, Autobahn Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors